GITNUXREPORT 2026

Vaccine Industry Statistics

The vaccine industry grew massively due to the pandemic, creating immense revenue and production.

Rajesh Patel

Team Lead & Senior Researcher with over 15 years of experience in market research and data analytics.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

In 2022, the global vaccine market was valued at $61.5 billion, with projections to reach $107.8 billion by 2030 at a CAGR of 7.4%.

Statistic 2

Pfizer reported $37.8 billion in COVID-19 vaccine revenue for 2021 alone.

Statistic 3

Moderna's 2022 revenue reached $18.4 billion, primarily from its Spikevax COVID-19 vaccine.

Statistic 4

GSK's vaccine sales grew 21% to £7.5 billion in 2022.

Statistic 5

Sanofi's vaccine division generated €5.7 billion in revenue in 2022.

Statistic 6

The U.S. vaccine market accounted for 46% of global revenue in 2022, totaling approximately $28.3 billion.

Statistic 7

AstraZeneca's Vaxzevria vaccine generated $4.3 billion in 2021 sales.

Statistic 8

Johnson & Johnson's vaccine revenue was $2.4 billion in 2021.

Statistic 9

Novavax reported $1.8 billion in preliminary 2022 vaccine sales.

Statistic 10

The HPV vaccine market alone was worth $5.1 billion globally in 2022.

Statistic 11

Merck's Gardasil 9 generated $6.5 billion in 2022 sales.

Statistic 12

Flu vaccine market valued at $7.2 billion in 2022.

Statistic 13

Bavarian Nordic's vaccine revenue surged 85% to DKK 1.8 billion in 2022.

Statistic 14

CSL's influenza vaccine sales hit A$1.2 billion in FY2022.

Statistic 15

Valneva's vaccine pipeline contributed €136 million in revenue in 2022.

Statistic 16

Global vaccine R&D spending reached $12.5 billion in 2022.

Statistic 17

Vaccine industry profits exceeded $100 billion cumulatively from COVID vaccines by 2023.

Statistic 18

BioNTech's 2022 revenue from Comirnaty was €17.8 billion.

Statistic 19

Seqirus flu vaccine sales were $1.5 billion in 2022.

Statistic 20

Emergent BioSolutions government contracts for vaccines totaled $1.2 billion in 2021.

Statistic 21

Dynavax's Heplisav-B sales reached $160 million in 2022.

Statistic 22

Global measles vaccine market size was $2.4 billion in 2022.

Statistic 23

Roche's vaccine diagnostics revenue was CHF 1.1 billion in 2022.

Statistic 24

Zydus Cadila's ZyCoV-D vaccine generated INR 1,000 crore in 2022.

Statistic 25

Serum Institute of India's vaccine exports worth $1.5 billion in 2022.

Statistic 26

Pfizer holds 32% global COVID vaccine market share in 2022.

Statistic 27

Moderna captured 18% of mRNA COVID vaccine market.

Statistic 28

AstraZeneca dominated Europe with 40% COVID vaccine share.

Statistic 29

Sinovac held 25% market share in Asia-Pacific COVID vaccines.

Statistic 30

Serum Institute supplied 60% of India's COVID vaccines.

Statistic 31

GSK leads shingles vaccine market with 70% share via Shingrix.

Statistic 32

Merck dominates HPV market with 85% share worldwide.

Statistic 33

Sanofi holds 40% of global pediatric vaccine market.

Statistic 34

Pfizer leads pneumococcal vaccines with Prevnar at 50% share.

Statistic 35

CSL Seqirus has 25% flu vaccine market share in U.S.,

Statistic 36

Novavax entered with 5% U.S. COVID booster market share in 2023.

Statistic 37

Bharat Biotech 20% share in India's COVID vaccine market.

Statistic 38

Sputnik V captured 15% of global COVID vaccine doses supplied.

Statistic 39

J&J Janssen 10% share of one-dose vaccines globally.

Statistic 40

Valneva secured 2% UK COVID booster market.

Statistic 41

Zydus ZyCoV-D 10% share in India.

Statistic 42

SK Bioscience growing to 5% Korean market.

Statistic 43

China Big Four (Sinovac, Sinopharm etc.) 40% global supply.

Statistic 44

EU centralized vaccines: Pfizer/Moderna 70% share.

Statistic 45

U.S. COVID market: Pfizer 60%, Moderna 35%.

Statistic 46

Low-income countries received only 20% of global doses.

Statistic 47

In 2022, over 13 billion COVID-19 vaccine doses were produced globally.

Statistic 48

Pfizer-BioNTech produced 3 billion doses of Comirnaty in 2022.

Statistic 49

Moderna manufactured 1 billion doses of Spikevax by end of 2022.

Statistic 50

AstraZeneca supplied 3 billion doses of Vaxzevria cumulatively by 2022.

Statistic 51

India produced 2.2 billion COVID-19 vaccine doses in 2022.

Statistic 52

Serum Institute of India manufactured 1.5 billion Covishield doses by 2022.

Statistic 53

Global flu vaccine production reached 1.8 billion doses annually by 2022.

Statistic 54

Sanofi Pasteur produced 500 million doses of influenza vaccines in 2022.

Statistic 55

GSK Shingrix production scaled to 200 million doses per year by 2022.

Statistic 56

Merck produced 300 million doses of HPV vaccines in 2022.

Statistic 57

Novavax manufactured 100 million doses of Nuvaxovid in 2022.

Statistic 58

Bharat Biotech produced 200 million Covaxin doses in 2022.

Statistic 59

Johnson & Johnson Janssen vaccine production hit 1 billion doses by 2022.

Statistic 60

Global pneumococcal vaccine production was 500 million doses in 2022.

Statistic 61

Valneva produced 60 million doses of VLA200 COVID vaccine in 2022.

Statistic 62

CSL Seqirus flu vaccine doses: 180 million in 2022.

Statistic 63

Zydus Cadila produced 50 million ZyCoV-D doses in 2022.

Statistic 64

Sputnik V production reached 2 billion doses capacity by 2022.

Statistic 65

Global rotavirus vaccine doses manufactured: 250 million in 2022.

Statistic 66

Sinovac produced 2 billion CoronaVac doses cumulatively by 2022.

Statistic 67

Annual global DTP vaccine production: 1.5 billion doses.

Statistic 68

SK Bioscience produced 100 million doses of COVID vaccines in 2022.

Statistic 69

Global vaccine R&D investment hit $14.4 billion in 2021.

Statistic 70

Pfizer invested $2.2 billion in COVID vaccine R&D in 2021.

Statistic 71

Moderna spent $3.4 billion on R&D in 2022, mostly vaccines.

Statistic 72

GSK R&D spend: £5.0 billion in 2022, 25% on vaccines.

Statistic 73

Sanofi allocated €6.5 billion to R&D, vaccines key focus.

Statistic 74

mRNA vaccine platforms received $25 billion in funding since 2020.

Statistic 75

Operation Warp Speed invested $18 billion in COVID vaccines.

Statistic 76

BARDA funded $3.1 billion for J&J vaccine development.

Statistic 77

CEPI committed $2 billion to COVID vaccine R&D.

Statistic 78

AstraZeneca R&D for Vaxzevria: $750 million.

Statistic 79

Novavax received $1.6 billion from U.S. for vaccine R&D.

Statistic 80

BioNTech R&D expenses: €2.1 billion in 2022.

Statistic 81

Merck invested $1.5 billion in pneumococcal vaccine R&D.

Statistic 82

J&J global R&D spend: $14.9 billion in 2022, vaccines included.

Statistic 83

Valneva R&D investment: €100 million for chikungunya vaccine.

Statistic 84

CureVac spent €300 million on mRNA vaccine R&D in 2022.

Statistic 85

Sinovac R&D budget: CNY 1.2 billion for vaccines.

Statistic 86

Bharat Biotech invested INR 1,500 crore in Covaxin R&D.

Statistic 87

Global RSV vaccine R&D funding: $5 billion since 2015.

Statistic 88

Pfizer's RSV vaccine R&D: $1 billion committed.

Statistic 89

Sanofi RSV vaccine partnership R&D: €500 million.

Statistic 90

Universal flu vaccine R&D global spend: $2.8 billion annually.

Statistic 91

HIV vaccine R&D funding: $1 billion per year globally.

Statistic 92

In VAERS, over 1.5 million COVID-19 vaccine adverse events reported by 2023.

Statistic 93

CDC reported 18,007 deaths following COVID-19 vaccination as of 2023.

Statistic 94

Pfizer's clinical trials showed 1 in 800 serious adverse events for Comirnaty.

Statistic 95

Moderna's vaccine associated with myocarditis at 40.6 cases per million doses in young males.

Statistic 96

AstraZeneca vaccine linked to 8.1 TTS cases per million first doses.

Statistic 97

J&J vaccine TTS rate: 3.83 cases per million doses.

Statistic 98

Anaphylaxis rate for mRNA vaccines: 5 per million doses.

Statistic 99

Guillain-Barré syndrome risk doubled after J&J vaccine.

Statistic 100

36,000+ neurological events reported in VAERS for Pfizer by 2023.

Statistic 101

Bell's palsy reported in 1% of Pfizer trial participants.

Statistic 102

Myocarditis hospitalization rate: 162 per million second doses in males 12-17.

Statistic 103

Pericarditis after Moderna: 52.4 cases per million in males 18-24.

Statistic 104

VAERS cardiac arrests: 2,500+ post-COVID vaccination by 2023.

Statistic 105

Thrombocytopenia after AstraZeneca: 11.1 per million doses.

Statistic 106

Miscarriage reports in VAERS: 30,000+ after COVID shots.

Statistic 107

EMA reported 50,648 deaths post-vaccination by Sept 2023.

Statistic 108

UK Yellow Card: 2.5 million adverse reactions to COVID vaccines.

Statistic 109

Flu vaccine associated with 1.4 excess Guillain-Barré cases per million.

Statistic 110

HPV vaccine fainting rates: 15% within 15 minutes post-injection.

Statistic 111

Shingrix adverse events: 20% severe reactions in trials.

Statistic 112

Rotavirus vaccine intussusception risk: 1-6 per 100,000 infants.

Statistic 113

DTaP vaccine seizures: 1 per 14,000 doses.

1/113

Sources

Trusted by 500+ publications

+497

While the vaccine industry saw staggering revenues—like Pfizer's $37.8 billion in 2021—and produced over 13 billion COVID-19 doses in 2022 alone, these monumental figures of commerce and scale are set against a complex backdrop of substantial public investment, profound market dominance, and ongoing discussions around safety and global equity.

Key Takeaways

In 2022, the global vaccine market was valued at $61.5 billion, with projections to reach $107.8 billion by 2030 at a CAGR of 7.4%.
Pfizer reported $37.8 billion in COVID-19 vaccine revenue for 2021 alone.
Moderna's 2022 revenue reached $18.4 billion, primarily from its Spikevax COVID-19 vaccine.
In 2022, over 13 billion COVID-19 vaccine doses were produced globally.
Pfizer-BioNTech produced 3 billion doses of Comirnaty in 2022.
Moderna manufactured 1 billion doses of Spikevax by end of 2022.
In VAERS, over 1.5 million COVID-19 vaccine adverse events reported by 2023.
CDC reported 18,007 deaths following COVID-19 vaccination as of 2023.
Pfizer's clinical trials showed 1 in 800 serious adverse events for Comirnaty.
Global vaccine R&D investment hit $14.4 billion in 2021.
Pfizer invested $2.2 billion in COVID vaccine R&D in 2021.
Moderna spent $3.4 billion on R&D in 2022, mostly vaccines.
Pfizer holds 32% global COVID vaccine market share in 2022.
Moderna captured 18% of mRNA COVID vaccine market.
AstraZeneca dominated Europe with 40% COVID vaccine share.

The vaccine industry grew massively due to the pandemic, creating immense revenue and production.

Financial Performance

In 2022, the global vaccine market was valued at $61.5 billion, with projections to reach $107.8 billion by 2030 at a CAGR of 7.4%.
Pfizer reported $37.8 billion in COVID-19 vaccine revenue for 2021 alone.
Moderna's 2022 revenue reached $18.4 billion, primarily from its Spikevax COVID-19 vaccine.
GSK's vaccine sales grew 21% to £7.5 billion in 2022.
Sanofi's vaccine division generated €5.7 billion in revenue in 2022.
The U.S. vaccine market accounted for 46% of global revenue in 2022, totaling approximately $28.3 billion.
AstraZeneca's Vaxzevria vaccine generated $4.3 billion in 2021 sales.
Johnson & Johnson's vaccine revenue was $2.4 billion in 2021.
Novavax reported $1.8 billion in preliminary 2022 vaccine sales.
The HPV vaccine market alone was worth $5.1 billion globally in 2022.
Merck's Gardasil 9 generated $6.5 billion in 2022 sales.
Flu vaccine market valued at $7.2 billion in 2022.
Bavarian Nordic's vaccine revenue surged 85% to DKK 1.8 billion in 2022.
CSL's influenza vaccine sales hit A$1.2 billion in FY2022.
Valneva's vaccine pipeline contributed €136 million in revenue in 2022.
Global vaccine R&D spending reached $12.5 billion in 2022.
Vaccine industry profits exceeded $100 billion cumulatively from COVID vaccines by 2023.
BioNTech's 2022 revenue from Comirnaty was €17.8 billion.
Seqirus flu vaccine sales were $1.5 billion in 2022.
Emergent BioSolutions government contracts for vaccines totaled $1.2 billion in 2021.
Dynavax's Heplisav-B sales reached $160 million in 2022.
Global measles vaccine market size was $2.4 billion in 2022.
Roche's vaccine diagnostics revenue was CHF 1.1 billion in 2022.
Zydus Cadila's ZyCoV-D vaccine generated INR 1,000 crore in 2022.
Serum Institute of India's vaccine exports worth $1.5 billion in 2022.

Financial Performance Interpretation

While the vaccine industry's astronomical revenue figures are a testament to brilliant science and global demand, they also starkly quantify the immense and ongoing price we pay—financially and as a society—to fend off the microscopic threats that constantly besiege us.

Global Market

Pfizer holds 32% global COVID vaccine market share in 2022.
Moderna captured 18% of mRNA COVID vaccine market.
AstraZeneca dominated Europe with 40% COVID vaccine share.
Sinovac held 25% market share in Asia-Pacific COVID vaccines.
Serum Institute supplied 60% of India's COVID vaccines.
GSK leads shingles vaccine market with 70% share via Shingrix.
Merck dominates HPV market with 85% share worldwide.
Sanofi holds 40% of global pediatric vaccine market.
Pfizer leads pneumococcal vaccines with Prevnar at 50% share.
CSL Seqirus has 25% flu vaccine market share in U.S.,
Novavax entered with 5% U.S. COVID booster market share in 2023.
Bharat Biotech 20% share in India's COVID vaccine market.
Sputnik V captured 15% of global COVID vaccine doses supplied.
J&J Janssen 10% share of one-dose vaccines globally.
Valneva secured 2% UK COVID booster market.
Zydus ZyCoV-D 10% share in India.
SK Bioscience growing to 5% Korean market.
China Big Four (Sinovac, Sinopharm etc.) 40% global supply.
EU centralized vaccines: Pfizer/Moderna 70% share.
U.S. COVID market: Pfizer 60%, Moderna 35%.
Low-income countries received only 20% of global doses.

Global Market Interpretation

Amidst a global chessboard where Pfizer's king holds 32% of the COVID crown, Moderna and AstraZeneca command their own regional fiefdoms, and GSK’s Shingrix lords over shingles with 70% dominion, the sobering checkmate remains that low-income nations are left holding a mere pawn’s share of just 20% of the doses.

Production Volumes

In 2022, over 13 billion COVID-19 vaccine doses were produced globally.
Pfizer-BioNTech produced 3 billion doses of Comirnaty in 2022.
Moderna manufactured 1 billion doses of Spikevax by end of 2022.
AstraZeneca supplied 3 billion doses of Vaxzevria cumulatively by 2022.
India produced 2.2 billion COVID-19 vaccine doses in 2022.
Serum Institute of India manufactured 1.5 billion Covishield doses by 2022.
Global flu vaccine production reached 1.8 billion doses annually by 2022.
Sanofi Pasteur produced 500 million doses of influenza vaccines in 2022.
GSK Shingrix production scaled to 200 million doses per year by 2022.
Merck produced 300 million doses of HPV vaccines in 2022.
Novavax manufactured 100 million doses of Nuvaxovid in 2022.
Bharat Biotech produced 200 million Covaxin doses in 2022.
Johnson & Johnson Janssen vaccine production hit 1 billion doses by 2022.
Global pneumococcal vaccine production was 500 million doses in 2022.
Valneva produced 60 million doses of VLA200 COVID vaccine in 2022.
CSL Seqirus flu vaccine doses: 180 million in 2022.
Zydus Cadila produced 50 million ZyCoV-D doses in 2022.
Sputnik V production reached 2 billion doses capacity by 2022.
Global rotavirus vaccine doses manufactured: 250 million in 2022.
Sinovac produced 2 billion CoronaVac doses cumulatively by 2022.
Annual global DTP vaccine production: 1.5 billion doses.
SK Bioscience produced 100 million doses of COVID vaccines in 2022.

Production Volumes Interpretation

The sheer scale of global vaccine manufacturing in 2022 reveals a scientific logistics miracle, where the production of COVID-19 shots alone dwarfed the annual global output of nearly every other vaccine we’ve ever relied on, all while these legacy programs kept dutifully humming along.

R&D Investment

Global vaccine R&D investment hit $14.4 billion in 2021.
Pfizer invested $2.2 billion in COVID vaccine R&D in 2021.
Moderna spent $3.4 billion on R&D in 2022, mostly vaccines.
GSK R&D spend: £5.0 billion in 2022, 25% on vaccines.
Sanofi allocated €6.5 billion to R&D, vaccines key focus.
mRNA vaccine platforms received $25 billion in funding since 2020.
Operation Warp Speed invested $18 billion in COVID vaccines.
BARDA funded $3.1 billion for J&J vaccine development.
CEPI committed $2 billion to COVID vaccine R&D.
AstraZeneca R&D for Vaxzevria: $750 million.
Novavax received $1.6 billion from U.S. for vaccine R&D.
BioNTech R&D expenses: €2.1 billion in 2022.
Merck invested $1.5 billion in pneumococcal vaccine R&D.
J&J global R&D spend: $14.9 billion in 2022, vaccines included.
Valneva R&D investment: €100 million for chikungunya vaccine.
CureVac spent €300 million on mRNA vaccine R&D in 2022.
Sinovac R&D budget: CNY 1.2 billion for vaccines.
Bharat Biotech invested INR 1,500 crore in Covaxin R&D.
Global RSV vaccine R&D funding: $5 billion since 2015.
Pfizer's RSV vaccine R&D: $1 billion committed.
Sanofi RSV vaccine partnership R&D: €500 million.
Universal flu vaccine R&D global spend: $2.8 billion annually.
HIV vaccine R&D funding: $1 billion per year globally.

R&D Investment Interpretation

The vaccine industry's massive R&D spending, from COVID's "warp speed" billions to the steady pursuit of elusive universal flu and HIV shots, reads like humanity's collective, wildly expensive bet against the universe's most creative and ruthless biological adversaries.

Safety Data

In VAERS, over 1.5 million COVID-19 vaccine adverse events reported by 2023.
CDC reported 18,007 deaths following COVID-19 vaccination as of 2023.
Pfizer's clinical trials showed 1 in 800 serious adverse events for Comirnaty.
Moderna's vaccine associated with myocarditis at 40.6 cases per million doses in young males.
AstraZeneca vaccine linked to 8.1 TTS cases per million first doses.
J&J vaccine TTS rate: 3.83 cases per million doses.
Anaphylaxis rate for mRNA vaccines: 5 per million doses.
Guillain-Barré syndrome risk doubled after J&J vaccine.
36,000+ neurological events reported in VAERS for Pfizer by 2023.
Bell's palsy reported in 1% of Pfizer trial participants.
Myocarditis hospitalization rate: 162 per million second doses in males 12-17.
Pericarditis after Moderna: 52.4 cases per million in males 18-24.
VAERS cardiac arrests: 2,500+ post-COVID vaccination by 2023.
Thrombocytopenia after AstraZeneca: 11.1 per million doses.
Miscarriage reports in VAERS: 30,000+ after COVID shots.
EMA reported 50,648 deaths post-vaccination by Sept 2023.
UK Yellow Card: 2.5 million adverse reactions to COVID vaccines.
Flu vaccine associated with 1.4 excess Guillain-Barré cases per million.
HPV vaccine fainting rates: 15% within 15 minutes post-injection.
Shingrix adverse events: 20% severe reactions in trials.
Rotavirus vaccine intussusception risk: 1-6 per 100,000 infants.
DTaP vaccine seizures: 1 per 14,000 doses.

Safety Data Interpretation

This sobering compilation of statistics, ranging from the expected aches of immunity to the tragic and rare outliers, underscores the critical, non-negotiable work of meticulously measuring medical risk against the catastrophic scale of a pandemic left unchecked.